Italia markets closed

CRVS Oct 2024 1.000 call

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
1,20000,0000 (0,00%)
In data: 03:13PM EDT. Mercato aperto.
Schermo intero
Chiusura precedente1,2000
Aperto1,2000
Denaro0,8500
Domanda1,2000
Prezzo d'esercizio1,00
Scadenza2024-10-18
Min-Max giorno1,2000 - 1,2000
Contratto - Min-MaxN/D
Volume2
Open Interest60
  • GlobeNewswire

    Corvus Pharmaceuticals Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma Following Meeting with FDA

    Plans to initiate soquelitinib potentially registrational Phase 3 clinical trial in Q1 2024 Company to host conference call and webcast tomorrow at 8:30 a.m. ET / 5:30 a.m. PT BURLINGAME, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, confirmed today that it completed an End-of-Phase/Pre-Phase 3 meeting with FDA on its plans to initiate a Phase 3 registrational clinical trial of soquelitinib (formerly CPI-818),

  • GlobeNewswire

    Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results

    Interim Phase 1/1b clinical results with soquelitinib and published clinical studies on mechanism of action continue to support potential of ITK inhibition as novel immunotherapy for hematologic and solid tumors Conference Call Today at 4:30 p.m. ET / 1:30 p.m. PT BURLINGAME, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for

  • GlobeNewswire

    Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter Financial Results on August 8, 2023

    Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PTBURLINGAME, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on August 8, 2023 at 4:30 pm ET (1:30 pm PT) to provide a business update and report second quarter 2023 financial results. The conference call can be accessed by dialing 1-855-327-6837 (toll-free domestic) or 1-63